I’ve written before about pancreatic NETs (pNETs), much of which has been on the awareness side of my advocacy work, particularly emphasising the differences with core Pancreatic Cancer (adenocarcinoma).
Pancreatic NETs are quite difficult to diagnose and treat, some of that difficulty is due to the location of the pancreas and accessibility for surgeons and radiographers. It’s not helped by the fact that most pNETs are non-functional making diagnosis more difficult as there is little clinical suspicion to scan, but also results in more late diagnoses.
Although biopsies are possible, mainly via endoscopic ultrasound or laparoscopy, it can still be difficult to reach. In some cases biopsies are not done until after surgical removal of tumours. The latter scenario plus surgery after a positive biopsy result does present an increased risk of morbidity and mortality. Consequently physicians (and patients) often have difficult decisions to make. I discussed some of these issues in my article “To cut or not to cut” which covers all types of NETs, but it’s particularly relevant to pNETs.
Many medical publications and many NET specialists will talk about the need to find and resect the primary tumour but with pancreatic primaries, there’s always some caution and this is reflected in NET Guidelines in most regions. The topic of remove or watch remains controversial in pancreatic NETs.
Types of Pancreatic neuroendocrine tumour surgery
In addition to classic debulking/cytoreductive surgery including for liver metastases, surgery on the pancreas is complicated and needs expert skills., Types include:
- Distal pancreatectomy: Surgery to remove the body and tail of the pancreas. The spleen may also be removed if cancer has spread to the spleen.
- Enucleation: Surgery to remove the tumour only. This may be done when cancer occurs in one place in the pancreas.
- Pancreatoduodenectomy (Whipple Surgery): A surgical procedure in which the head of the pancreas, the gallbladder, nearby lymph nodes and part of the stomach, part of the small intestine, and bile duct are removed. Enough of the pancreas is left to make digestive juices. The organs removed during this procedure depend on the patient’s condition. There can be variations of this (plus or minus) depending on circumstances.
- Total pancreatectomy. This operation removes the entire pancreas, as well as the gallbladder, part of the stomach and small intestine, and the spleen. This surgery might be an option if the cancer has spread throughout the pancreas but can still be removed. But this type of surgery is used less often than the other operations because there doesn’t seem to be a major advantage in removing the whole pancreas, and it can have major side effects.
Pancreatic NETs – To cut or not to cut
There are guidelines for treatment of pNETs and most seem to have tumour size thresholds to aid decision making but that is just one factor. I’ve listened to many presentations by NET specialists talking about the dilemma of cutting or not cutting and the ‘debate’ is still happening 3 years since I took an interest in the subject. Most guidelines seem to use 2cm as a threshold for surgical removal (>2cm) or watch and wait (<2cm) but there are other factors which could also indicate surgical removal such as a functioning tumour producing one of the pNET syndromes (i.e. palliative surgery) or the tumour threatening important vessels (i.e. pre-emptive surgery). These guidelines include ENETS, NANETS and NCCN. Currently it’s difficult for physicians to know how aggressive a pNET could become over time and this hinders decision making.
As indicated above, often the decision to cut or not to cut is made easier when a patient is symptomatic, exhibiting signs of one of the pancreatic NET syndromes, this helps in decision making regardless of tumour size as the surgery becomes palliative in approach. However, most pancreatic NETs are non-functional. This 2020 paper here is therefore very interesting and also touches on the subject of whether the primary tumour be resected in the setting of unresectable metastatic disease? Pancreatic surgery is a big deal so always consult your specialists for further advice. Read more here.
For those interested in this debate, you may like a recent article from the 2019 Society of Surgical Oncology Annual Cancer Symposium where Cristina R. Ferrone, MD, the surgical director of the liver program in the Division of General Surgery at Massachusetts General Hospital, in Boston, and Peter J. Allen, MD, the chief of surgical oncology at Duke Cancer Institute, in Durham, N.C., describe the benefits of resection versus observation in small neuroendocrine tumors of the pancreas and outlined the risks of under- and over-treatment, respectively. Click here. It’s two sides of the coin and you may find the discussion interesting.
You may also find this NET Research Foundation sponsored video interesting from very well known and respected NET surgeon Dr James Howe. The link will take you directly to the part about pancreatic surgery (10.30). Click here to watch.
Summary and further reading
Of course what we really need is better prognostic testing which will help to guide therapy decisions, in particular surgery. Read my article on molecular research for Neuroendocrine Neoplasms (to follow, currently in draft but will be drawn from some of the references below).
1. Subtypes of Pancreatic Neuroendocrine Tumors and Effect on Disease Recurrence – By The ASCO Post, posted: 15 Jul 2019.
2. Robust molecular stratification provides insights into cell lineage correlates – By ESMO posted 09 Jul 2019.
3. NET Research Blog – NETRF-Funded Finding May Help Predict Pancreatic NET (pNET) Recurrence posted 1 Jul 2019.
4. Daxx Mutations – click here
Thanks for reading.
PLEASE SHARE THIS POST
Share on facebook Facebook Share on twitter Twitter Share on pinterest Pinterest Share on whatsapp WhatsApp Share on email Email A lot had been written
Share on facebook Facebook Share on twitter Twitter Share on pinterest Pinterest Share on whatsapp WhatsApp Share on email Email Xencor, a clinical-stage biopharmaceutical company
Share on facebook Facebook Share on twitter Twitter Share on pinterest Pinterest Share on whatsapp WhatsApp Share on email Email CLARINET FORTE is a prospective